Citations

Clear

18 citation(s) found for "Schatz, M".

Comparative survival and time toxicity outcomes of CAR-T versus bispecific antibody therapies in relapsed/refractory FL
Ahmed, Nausheen , Nogueira Serodio, Alline , Villasboas, Jose Caetano , Sharp, John , Voorhees, Timothy J , Houshyar, Samin , Wallace, Danielle S , Wagner, Charlotte , Bock, Allison M , Brooks, Taylor R , Al Any, Haya, Rajab, Mohamed , Gupta, Supriya , Karmali, Reem , Trotier, Daniel C , Pophali, Priyanka , Ricker, Edd , Cherng, Hua-Jay J , Torka, Pallawi , Trabolsi, Asaad , Schatz, Jonathan H , Gupta, Arjun

Mayo Clinic

Blood Advances | October 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026020899 | PMID 42962270 Get It

Chimeric antigen receptor T-cell (CAR-T) and CD20xCD3 bispecific antibody (BsAb) therapies are both effective for relapsed/refractory (R/R) follicular lymphoma (FL), but comparative real-world survival outcomes and time toxicity have not been characterized. We performed a multicenter retrospective study of 228 patients with R/R FL treated with standard-of-care CAR-T (n = 141) or BsAb (n = 87) across 17 U.S. academic centers in the third-line or later setting. Progression-free survival (PFS) and overall survival (OS) were stratified by 2 or ≥3 prior lines of therapy (LOT2 or LOT3+), including propensity matching. Time toxicity was measured by physical health care contact days. Median PFS was not reached (NR) with CAR-T and 581 days with BsAb in the LOT2 cohort (p < .0001), and was NR with CAR-T and 584 days with BsAb in the LOT3+ cohort (p = .0064). CAR-T recipients were younger (p < .0001) and had better performance status (p = .007) but were more refractory to prior LOT (p = .017). PFS advantages of CAR-T were independent of these differences. OS did not differ between treatment groups. CAR-T had significantly greater time toxicity over the first year, with higher mean contact days than BsAb in both the LOT2 (58 vs 44) and LOT3+ (69 vs 49) cohorts. In this large multicenter cohort of patients with R/R FL, CAR-T was associated with superior PFS but greater time toxicity compared with BsAb therapy. These findings provide real-world outcomes data and time toxicity benchmarks to support treatment sequencing decision-making in R/R FL.
An Overview of Cannabinoid Interactions With Common Pediatric Antineoplastic Agents
Zaman, Shatila, Schatz, Mollie, Kuhn, Alexis , O’Keefe, Madeleine, Greenmyer, Jacob R. , Smith, Melissa K, Martin, Catherine E. , Kuhn, Alexis K , O'Keefe, Madeleine B, DeFino, Catherine E.

Mayo Clinic

Pediatric Blood & Cancer | April 30, 2026 | Volume: 73 | Issue: 7 | Pages: No page available

10.1002/1545-5017.70336 | PMID 42057496 Get It

ABSTRACT As interest in the use of cannabinoids for supportive care in pediatric cancers grows, there are emerging concerns about potential interactions with antineoplastic agents. This review provides an overview of potential drug–drug interactions between cannabinoids and 25 antineoplastic agents commonly used in pediatric hematology/oncology. Antineoplastic agents were stratified into low, medium, or high interaction risk based on the potential impact of cannabinoids on metabolic and/or pharmacodynamic pathways. The antineoplastic agents identified as high risk for interactions with cannabinoids included cyclophosphamide, doxorubicin, etoposide, ifosfamide, irinotecan, vinblastine, and vincristine. Key mechanisms of interaction include inhibition of cytochrome P450 enzymes and UDP‐glucuronosyltransferases and modulation of drug transporters such as P‐glycoprotein and breast cancer resistance protein. There is emerging evidence of a synergistic effect between cannabinoids and antineoplastic agents such as temozolomide, vinblastine, vinorelbine, and irinotecan. Pediatric patients exhibit developmental differences in drug metabolism and transporter expression, yet most pharmacokinetic data on cannabinoids are extrapolated from adult studies. There is a lack of pediatric‐specific safety, efficacy, and dosing data that underscores the need for age‐appropriate studies to ensure safe and effective integration of cannabinoids in pediatric cancer care.
Frontline chemotherapy for CD30+ non-ALCL peripheral T-cell lymphoma a multi-center retrospective analysis
Han, Sunwoo , Johnson, William T. , Lingamaneni, Prasanth , Shastri, Toral, Panjrolia, Ekta, Rojas-Neira, Estela, Ayers, Amy , Jayram, Diya, Ho, Phuong , Treitman, Rachel, Chinniah, Siven, Sethi, Tarsheen , Ganesan, Nivetha, Chang, Tiffany , Qureshi, Haris, Haverkos, Bradley M. , Epstein‐Peterson, Zachary D. , Moskowitz, Alison J. , Ansell, Stephen, Trabolsi, Asaad , Johnson, William, Stuver, Robert , Ho, Phuong, Weiss, Julian J , Saeed, Hayder , Foss, Francine M. , Malpica, Luis , Bennani, N. Nora , Zhang, Yumeng , Horwitz, Steven M. , Schatz, Jonathan H

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 3641-3641

10.1182/blood-2025-3641 Get It

Abstract INTRODUCTION The ECHELON-2 trial for newly diagnosed CD30+ peripheral T-cell lymphomas (PTCL) demonstrated superior overall survival with brentuximab vedotin plus chemotherapy (BV-CHP) compared to CHOP. However, total enrollment was restricted to only 30% of patients with non-anaplastic large cell lymphoma (ALCL) histologies and was not powered to analyze survival benefits in this cohort. Thus, the benefit of BV-CHP in non-ALCL patients remains less clear. Adding to this uncertainty, CHOP plus etoposide (CHOEP) remains a standard regimen for many non-ALCL PTCL histologies for patients <60 years of age. Which of these three regimens offers superior outcomes for patients with CD30+ non-ALCL PTCL remains to be determined, is a critical knowledge gap in this area, and could meaningfully inform the management of these patients. METHODS We conducted a retrospective analysis of chemotherapy-naïve CD30+ (≥1%) PTCL from 7 centers in the United States. Histologies were limited to PTCL-NOS and PTCL with a T follicular helper phenotype (PTCL-TFH). Frontline regimens were defined as BV-based (BV-CHP), etoposide-based (CHOEP/EPOCH), novel-CHOP (CHOP/CHOEP + novel drug on a clinical trial), or CHOP. CD30 was considered positive if any expression was reported, and when available, stratified as ≥10% or <10% of the total lymphocyte population. RESULTS The CD30+ PTCL cohort consisted of 194 patients with a median age of 68 years at diagnosis and a male (65%) predominance. Nodal PTCL-TFH (65%) was the most common histology. Most had stage III-IV disease (89%) with a high-intermediate to high-risk IPI score of 3-5 (54%). 18% had an ECOG of ≥2, 45% had ≥2 extranodal sites, and 43% had bone marrow involvement, although biopsies were not performed in all patients. CD30 expression in ≥10% of malignant T cells was observed in 55% of all quantitatively reported cases. Frontline therapy consisted of BV-based (36%), etoposide-based (30%), CHOP (27%), and novel-CHOP (7%). Baseline characteristics and CD30 expression were similar between treatment groups. The ORR was 72% (64% CR, 8% PR), with no differences observed by treatment or histology. On multivariate analysis (MVA), a high LDH was associated with lower CR (OR 2.84, p=0.003). For the patients who demonstrated a CR to frontline therapy, 61% underwent ASCT. With a median follow-up of 26.1 months (IQR 12.3-51.6), the median PFS and OS were 11.4 (9.8-14.2) and 47 (32-60.3) months, respectively. The 2-year PFS and OS were 34.9% (28.1-41.7) and 62% (54.5-68.6), respectively. PFS and OS were similar for PTCL-NOS compared to PTCL-TFH, and AITL fared similarly to non-AITL PTCL-TFH. By treatment, novel-CHOP demonstrated the most favorable PFS (median 41.9 months) and OS (median 68.1 months). Survival curves overlapped continuously with all other treatment regimens and was not statistically significant. For patients <60, PFS and OS were equivocal with BV-based (n=17) compared to etoposide-based (n=26) regimens. On MVA, stage III/IV disease conferred an inferior PFS (HR 2.00, p=0.018) as did an IPI score of 3-5 for OS (HR 2.15, p=0.001). Neither histology nor frontline treatment impacted PFS or OS. The chosen frontline treatment also had no survival impact in key subgroup analyses including patients <60 (n=56) or with CD30-expression ≥10% (n=43). For patients with CR to frontline therapy, ASCT demonstrated a significant PFS benefit (HR 0.59, p=0.028) but no statistically significant difference in OS benefit (HR 0.58, p=0.073). CONCLUSION These data provide valuable insight into the lesser-represented patient population from the pivotal ECHELON-2 trial. In this cohort of CD30+ (≥1%) non-ALCL PTCL, there was no clearly superior standard frontline regimen. The number of patients with quantitively reported CD30 expression was too small for definitive conclusions in the ≥10% CD30+ cohort and retrospective pathology review is ongoing. ASCT for patients in CR offered superior outcomes, supporting this strategy regardless of the frontline regimen, recognizing the limitations of non-randomized, retrospective analyses. Novel-CHOP regimens demonstrated encouraging survival, and clinical trials should maintain priority over standard regimens for patients with CD30+ (1-10%) PTCL-NOS and PTCL-TFH.
166 Development of Hypothesised Conceptual Framework for Major Abdominal Surgery
Courtney, Aisling E. , Schatz, Michael, Dorudi, Sina, Courtney, A, Schatz, M, Vindrola‐Padros, Cecilia , Windsor, Alastair C. J. , Moonesinghe, Ramani

Mayo Clinic

British Journal of Surgery | June 27, 2025 | Volume: 112 | Issue: Supplement_10 | Pages: No page available

10.1093/bjs/znaf128.654 Get It

Abstract Aim Major abdominal surgery (MAS) can have a diverse impact on patient’s life, including physical, emotional and socio-economic effects. At present, there is no patient reported outcome (PRO) instrument that was specifically developed for MAS population. The aim of this study was to develop a hypothesised conceptual framework of the key domains that underpin the process of recovery following major abdominal surgery in the adult population. This framework will serve as a foundation for developing a valid PRO instrument for the target population of interest. Method The development of the hypothesised conceptual framework included the following stages: 1) defining major abdominal surgery and verification of its discriminative properties, 2) systematic review of currently available PRO instruments, 3) mapping of the domains within identified PRO instruments to WHO International Classification of Functioning, Disability and Health (ICF) conceptual framework, 4) derivation of the hypothesised conceptual framework by linking of the ICF domains and the health-related quality of life theoretical framework. Results Fourteen PRO instruments were identified by the systematic review. The individual PRO items within each instrument collectively covered 25 ICF domains and 53 sub-domains. A hypothesised conceptual framework was derived based on the “conceptual model of health-related quality of life” and the ICF framework, applied within three principles of exposure, moderating factors and outcomes. Conclusions This study proposed a hypothesised conceptual framework for the development of PRO instruments to evaluate recovery following major abdominal surgery. However, its relevance, content validity and comprehensiveness remain to be examined in future studies.
Abstract 5638: Autologous CD34+ Cell Therapy for Refractory Angina: 12 Month Results of the Phase II ACT34-CMI Study
Henry, Tim, Schatz, Richard A. , Lee, Joon Sup, Bass, Theodore A., Schaer, Gary L. , Niederman, Alan, Mendelsohn, Farrell O., Davidson, Charles J. , Waksman, Ron , Soukas, Peter , Simon, Daniel I. , Chronos, Nicolas, Fortuin, F. David , Wong, S. Chiu, Taussig, Andrew, Rava, Amish N, Sherman, Warren, Kereiakes, Dean J. , Strumpf, Robert K., Port, Steven, Pieper, Karen S. , Adams, Peter X., Harrington, Robert A. , Losordo, Douglas W. , Costa, Marco Antonio , Davidson, Charles J. , Huang, Paul P. , Weintraub, Neal L. , Yeung, Alan C. , Rosenfield, Kenneth , Port, Steven C.

Mayo Clinic

Circulation | April 23, 2024 | Volume: 120 | Issue: suppl_18 | Pages: No page available

10.1161/circ.120.suppl_18.s1132-a Get It

Background: Refractory angina(Ang) effects 150 –250,000 pts in the US alone. These individuals have exhausted options for revasc and continue to have lifestyle limiting ang despite optimal medical Rx. Pre-clinical studies provided evidence that human CD34+ cells(CD34) can stimulate new blood vessel formation in ischemic myocardium(Myo), improving perfusion and function. We performed a phase 2 study of intraMyo injection of autologous CD34 in pts with CCS Class 3 and 4 Ang to obtain evidence for feasibility, safety and bioactivity. Methods: A phase 2 randomized, double-blind, placebo-controlled clinical trial was performed at 26 centers in the United States. There were 3 treatment groups: placebo, low dose (1×10^5 CD34/kg body wt) and high dose (5×10^5 CD34/kg). All pts underwent mobilization with GCSF 5 mcg/kg/day SC for 5 d, followed by apheresis on d5 to collect mononuclear cells. On day 6 CD34 were purified from the collected cells using the Isolex 300i device. After lot release testing, CD34 were injected endocardially at 10 locations in the ischemic Myo using the Myostar catheter following NOGA mapping. Placebo injections consisted of identical volumes of the diluent only. Results: A total of 167 pts were randomized and completed the injection procedure and 162 completed the 6 mo evaluation. The mean age of subjects was 61.0±8.9, there were 22 female and 145 male subjects. Trop was elevated in 26 pts at baseline and in 71 at some point following GCSF or injection. At 6 mo CD34 treated pts showed more reduction in ang frequency (−8.6 placebo vs 14.2 low dose) and improved ETT time (+69 sec placebo vs. +138 low dose). At 12m CD34 treated continue to show more reduction in angina (−8.2 placebo vs. −15.0 low dose) and improved ETT (+58 sec placebo vs. + 139 sec low dose). For key endpoints the high dose group results were inferior to low dose. The 12m data set has been locked and is being analyzed and the results of the completed analysis will be presented. Conclusions: Autologous CD34 cell therapy was associated with improved exercise tolerance and reduced angina in no-option pts with intractable angina. Ongoing analysis will determine endpoints, sample size and suitability of this therapy for a phase III study in no-option pts with refractory angina.
Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions
Major, Ajay , Yu, Jovian , Shukla, Navika , Karrison, Theodore , Treitman, Rachel, Haverkos, Bradley M. , Godfrey, James , Babcook, Melissa A., Voorhees, Timothy , Carlson, Sophie G. , Gaut, Daria , Oliai, Caspian , Winter, Allison , Hill, Brian T. , Bansal, Radhika , Nizamuddin, Imran , Fitzgerald, Lindsey , Stephens, Deborah M. , Hu, Marie , Bachanová, Veronika , Slade, Michael , Singh, Nathan , Bishop, Michael R. , Riedell, Peter A. , Haverkos, Bradley M , Voorhees, Timothy J , Romancik, Jason T , Bansal, Radhika , Villasboas, Jose Caetano , Karmali, Reem , Stephens, Deborah M , Pophali, Priyanka , Trabolsi, Asaad , Schatz, Jonathan H , Hu, Marie , Slade, Michael J , Singh, Nathan , Ahmed, Nausheen , McGuirk, Joseph , Riedell, Peter A , Bachanova, Veronika , Major, Ajay , Che, Yan, Kamdar, Manali , Oliai, Caspian H , Romancik, Jason T. , Villasboas, José C. , Karmali, Reem , Pophali, Priyanka A. , Ahmed, Nausheen , McGuirk, Joseph P. , Bishop, Michael Russell , Kline, Justin Paul

Mayo Clinic

Blood Advances | April 7, 2023 | Volume: 7 | Issue: 16 | Pages: 4528-4538

10.1182/bloodadvances.2023010016 | PMID 37026796 Get It

AbstractCheckpoint inhibitor (CPI) therapy with anti–PD-1 antibodies has been associated with mixed outcomes in small cohorts of patients with relapsed aggressive B-cell lymphomas after CAR-T failure. To define CPI therapy efficacy more definitively in this population, we retrospectively evaluated clinical outcomes in a large cohort of 96 patients with aggressive B-cell lymphomas receiving CPI therapy after CAR-T failure across 15 US academic centers. Most patients (53%) had diffuse large B-cell lymphoma, were treated with axicabtagene ciloleucel (53%), relapsed early (≤180 days) after CAR-T (83%), and received pembrolizumab (49%) or nivolumab (43%). CPI therapy was associated with an overall response rate of 19% and a complete response rate of 10%. Median duration of response was 221 days. Median progression-free survival (PFS) and overall survival (OS) were 54 and 159 days, respectively. Outcomes to CPI therapy were significantly improved in patients with primary mediastinal B-cell lymphoma. PFS (128 vs 51 days) and OS (387 vs 131 days) were significantly longer in patients with late (>180 days) vs early (≤180 days) relapse after CAR-T. Grade ≥3 adverse events occurred in 19% of patients treated with CPI. Most patients (83%) died, commonly because of progressive disease. Only 5% had durable responses to CPI therapy. In the largest cohort of patients with aggressive B-cell lymphoma treated with CPI therapy after CAR-T relapse, our results reveal poor outcomes, particularly among those relapsing early after CAR-T. In conclusion, CPI therapy is not an effective salvage strategy for most patients after CAR-T, where alternative approaches are needed to improve post–CAR-T outcomes.
Distinct Chemokine Receptor Expression Profiles in De Novo DLBCL, Transformed Follicular Lymphoma, Richter’s Trans-Formed DLBCL and Germinal Center B-Cells
Uhl, Barbara , Pansy, Katrin , Wenzl, Kerstin , Strobl, Johanna , Baumgartner, Claudia , Szmyra, Marta , Waha, James Elvis, Wolf, Axel , Tomazic, Peter Valentin , Steinbauer, Elisabeth, Steinwender, Maria, Friedl, Sabine, Weniger, Marc A., Küppers, Ralf , Pichler, Martin , Greinix, Hildegard , Ramsay, Alan G. , Apollonio, Benedetta , Feichtinger, Julia , Beham‐Schmid, Christine, Neumeister, Peter , Deutsch, Alexander , Pansy, Katrin , Strobl, Johanna , Küppers, Ralf , Pichler, Martin , Ramsay, Alan G , Feichtinger, Julia , Deutsch, Alexander J , Prochazka, Katharina Theresa , Baumgartner, Claudia, Stary, Georg

Mayo Clinic

International Journal of Molecular Sciences | July 17, 2022 | Volume: 23 | Issue: 14 | Pages: 7874

10.3390/ijms23147874 | PMID 35887224 Get It

Chemokine receptors and their ligands have been identified as playing an important role in the development of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and Richter syndrome (RS). Our aim was to investigate the different expression profiles in de novo DLBCL, transformed follicular lymphoma (tFL), and RS. Here, we profiled the mRNA expression levels of 18 chemokine receptors (CCR1–CCR9, CXCR1–CXCR7, CX3CR1 and XCR1) using RQ-PCR, as well as immunohistochemistry of seven chemokine receptors (CCR1, CCR4–CCR8 and CXCR2) in RS, de novo DLBCL, and tFL biopsy-derived tissues. Tonsil-derived germinal center B-cells (GC-B) served as non-neoplastic controls. The chemokine receptor expression profiles of de novo DLBCL and tFL substantially differed from those of GC-B, with at least 5-fold higher expression of 15 out of the 18 investigated chemokine receptors (CCR1–CCR9, CXCR1, CXCR2, CXCR6, CXCR7, CX3CR1 and XCR1) in these lymphoma subtypes. Interestingly, the de novo DLBCL and tFL exhibited at least 22-fold higher expression of CCR1, CCR5, CCR8, and CXCR6 compared with RS, whereas no significant difference in chemokine receptor expression profile was detected when comparing de novo DLBCL with tFL. Furthermore, in de novo DLBCL and tFLs, a high expression of CCR7 was associated with a poor overall survival in our study cohort, as well as in an independent patient cohort. Our data indicate that the chemokine receptor expression profile of RS differs substantially from that of de novo DLBCL and tFL. Thus, these multiple dysregulated chemokine receptors could represent novel clinical markers as diagnostic and prognostic tools. Moreover, this study highlights the relevance of chemokine signaling crosstalk in the tumor microenvironment of aggressive lymphomas.
Artificial Intelligence and Cardiovascular Genetics
Krittanawong, Chayakrit , Johnson, Kipp W. , Choi, Edward , Kaplin, Scott , Venner, Eric , Murugan, Mullai , Glicksberg, Benjamin S. , Amos, Christopher I. , Schatz, Michael C. , Tang, W.H. Wilson , Glicksberg, Benjamin , Amos, Christopher I , Schatz, Michael C , Tang, W H Wilson , Venner, Eric , Wang, Zhen

Mayo Clinic

Life | February 14, 2022 | Volume: 12 | Issue: 2 | Pages: 279

10.3390/life12020279 | PMID 35207566 Get It

Polygenic diseases, which are genetic disorders caused by the combined action of multiple genes, pose unique and significant challenges for the diagnosis and management of affected patients. A major goal of cardiovascular medicine has been to understand how genetic variation leads to the clinical heterogeneity seen in polygenic cardiovascular diseases (CVDs). Recent advances and emerging technologies in artificial intelligence (AI), coupled with the ever-increasing availability of next generation sequencing (NGS) technologies, now provide researchers with unprecedented possibilities for dynamic and complex biological genomic analyses. Combining these technologies may lead to a deeper understanding of heterogeneous polygenic CVDs, better prognostic guidance, and, ultimately, greater personalized medicine. Advances will likely be achieved through increasingly frequent and robust genomic characterization of patients, as well the integration of genomic data with other clinical data, such as cardiac imaging, coronary angiography, and clinical biomarkers. This review discusses the current opportunities and limitations of genomics; provides a brief overview of AI; and identifies the current applications, limitations, and future directions of AI in genomics.
Abstract 12754: Infused CD34 Cell Dose, not Bone Marrow CD34+ Cell Content, Improves Clinical Outcomes and LVEF in Patients With Left Ventricular Dysfunction post STEMI: Results of the PreSERVE-AMI Trial
Kereiakes, Dean J. , Shavelle, David M. , Henry, Timothy D. , Toma, Catalin , Barsness, Gregory W. , Frohwein, Steve, Schatz, Richartd A, Cohen, Martin, Davidson, Charles J., Klapholz, Marc, Schaer, Gary L. , Moss, Thomas J. , Kanakaraj, AnnaMaria, Druker, Vitaly , Harper, Ken, Chung, Amy M. , Junge, Candice, Preti, Robert A., Smith, Robin L., Mazzo, David J., Pecora, Andrew L. , Quyyumi, Arshed A. , Abdel‐Latif, Ahmed , Schatz, R A, Dib, Nabil , Vásquez, Alejandro Arias , Kanakaraj, Anna Maria, Harper, Ken, Chung, Amy, Mazzo, David J., Losordo, Douglas W.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.12754 Get It

Background: Prior studies suggest an association between naturally high circulating levels of CD34+ cells (CD34) and better outcomes following ischemic events. Pts in the treatment arm of the PreSERVE-AMI study were infused with all CD34 yielded from their bone marrow harvest, resulting in pts with naturally higher CD34 cell counts being infused with a higher cell dose. To determine whether selection bias may have influenced results, we performed an analysis of the relationship between BM CD34 content and outcomes in PreSERVE-AMI. Methods: PreSERVE-AMI is a Phase 2, randomized, double-blind, placebo-controlled trial of autologous, BM derived CD34 (CLBS10) in pts with LV dysfunction (LVEF ≤48% by MRI) ≥4 days post-STEMI. All pts underwent mini BM harvest and were randomized 1:1 to intracoronary infusion of CD34 (minimum dose 10M±20% cells) or placebo (cell diluent). Primary safety endpoints included AEs, SAEs and MACE (CV mortality, HF hospitalization, reinfarction, revascularization). Secondary endpoints included LVEF change from baseline. Regression analyses were performed to assess the influence of BM CD34 content on outcomes. Results: 161 patients were randomized and received intracoronary infusion (Jan 2013-Dec 2014). Mean age was 57±10 and 82% were men. Mean follow-up time was 18 mo, and safety data are accruing. BM CD34 content was not associated with differences in baseline characteristics with the exception of diabetes prevalence being higher in those with higher BM CD34 count (p=0.03). In controls, regression analyses showed no association of BM CD34 content with rates of MACE (p=0.2), SAEs (p=0.4), or change in LVEF (p=0.9). However, in CD34 treated pts, there was a dose-dependent improvement in LV function (p=0.045) and dose-dependent trends in MACE and SAE reduction compared to controls. As previously reported SPECT perfusion improved to a similar degree in control and treated pts. Conclusions: These data suggest that intracoronary infusion of CD34 cells, rather than BM CD34 cell content, is responsible for the benefit observed in the CD34 treatment group. The finding of a dose-response relationship is an important advance for defining the CD34 as an active agent for tissue repair. Future studies will further define CD34 dosimetry.